Louisiana 2025 Regular Session

Louisiana House Bill HB535

Introduced
4/4/25  
Refer
4/4/25  
Refer
4/14/25  
Report Pass
5/20/25  
Refer
5/21/25  
Report Pass
5/27/25  
Engrossed
6/2/25  

Caption

Requires the Louisiana Legislative Auditor to evaluate state tax incentives (RRF +$43,000 GF EX See Note)

Impact

This legislation aims to increase accountability and transparency in the administration of tax incentives, as evaluations will provide critical data on job creation, income effects, and local sales tax impacts. The LLA is tasked with preparing cost-benefit analyses to assess both the effectiveness of these incentives and their overall impact on state revenue. This shift could significantly alter the landscape of economic development initiatives within the state, reinforcing the necessity for justifying the fiscal benefits of such programs.

Summary

House Bill 535 requires the Louisiana Legislative Auditor (LLA) to conduct evaluations on state tax incentives and economic development programs. The bill repeals existing laws that mandated specific performance audits and annual reports. Instead, it establishes a framework for the LLA to evaluate these programs on a quadrennial basis, ensuring a comprehensive review of their impact and effectiveness. The LLA will also have the authority to exempt certain incentives from evaluation if deemed to have minimal fiscal impact, broadening its capacity for oversight.

Sentiment

The sentiment surrounding HB 535 appears to prioritize the need for accountability in government spending and tax incentives. Proponents argue that thorough evaluations will enhance the effectiveness of economic development strategies and ensure that taxpayer dollars are utilized efficiently. Conversely, there may be concerns among businesses regarding potential scrutiny and changes in eligibility for tax incentives, which could lead to apprehension about the future of existing programs.

Contention

Notable points of contention in discussions around HB 535 include the balance between effective oversight and administrative burden on businesses. Some stakeholders worry that increased evaluations could impede economic growth, while others emphasize the importance of data-driven assessments to ensure that tax incentives fulfill their intended purposes. Amendments to the bill aimed at clarifying definitions and evaluation criteria reflect ongoing negotiations to strike a balance between necessary oversight and the interests of economic development.

Companion Bills

No companion bills found.

Similar Bills

RI S2086

Prohibits healthcare entities from interfering with a patient's right to choose to obtain a clinician-administered drug from their provider or pharmacy of choice.

RI H7365

Provides that health insurers provide coverage for covered clinician-administered drugs under certain circumstances.

RI H5680

Accident And Sickness Insurance Policies

RI S0870

Accident And Sickness Insurance Policies

NJ A797

Limits upfront costs for oral anticancer medications for persons covered under certain health benefits plans.

NJ A2464

Limits upfront costs for oral anticancer medications for persons covered under certain health benefits plans.

RI H8254

Accident And Sickness Insurance Policies

CA AB590

State-funded assistance grants and contracts: advance payments.